Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBP5 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Minnesota
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraarticular
01
Overview
GBP5 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Guanylate Binding Protein 5 (GBP5). GBP5 is a member of the interferon-inducible large GTPase family and has been identified as a driver of malignancy in glioblastoma (GBM), particularly the mesenchymal subtype. By targeting the Src/ERK1/2/MMP3 signaling axis, GBP5 siRNA inhibits the proliferation, migration, and invasion of GBM cells. Preclinical studies conducted at the University of Minnesota have demonstrated that silencing GBP5 results in impaired tumor growth and improved survival in mouse models of glioblastoma, suggesting its potential as a therapeutic target for brain tumors.
- Other names
- siRNA targeting GBP5Guanylate binding protein 5 small interfering RNA
02
Targets
GBP5 (Guanylate-binding protein 5)
Beyond the preview
Go deeper on GBP5 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBP5 siRNA.